Tumour infiltrating lymphocytes - Iovance Biotherapeutics/H. Lee Moffitt Cancer Center and Research Institute

Drug Profile

Tumour infiltrating lymphocytes - Iovance Biotherapeutics/H. Lee Moffitt Cancer Center and Research Institute

Alternative Names: TIL - Iovance Biotherapeutics/H. Lee Moffitt Cancer Center and Research Institute

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iovance Biotherapeutics
  • Developer Bristol-Myers Squibb; H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 11 Oct 2017 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (NCT03215810)
  • 24 Aug 2017 Preclinical trials in Non-small cell lung cancer in USA (IV) (Iovance Biotherapeutics, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top